Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Published:2018-08-23 Issue:1 Volume:46 Page:65-79
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Burggraaff Coreline N.,de Jong Antoinette,Hoekstra Otto S.,Hoetjes Nikie J.,Nievelstein Rutger A. J.,Jansma Elise P.,Heymans Martijn W.,de Vet Henrica C. W.,Zijlstra Josée M.

Funder

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-018-4103-3/fulltext.html

Reference57 articles.

1. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7:379–91.

2. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

3. Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–37.

4. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–94.

5. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80. Erratum in: J Clin Oncol. 2011; 29: 779

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas;PET Clinics;2024-10

2. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies;Trends in Molecular Medicine;2024-07

3. Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review;Critical Reviews in Oncology/Hematology;2024-04

4. Quarter-Century PET/CT Transformation of Oncology: Lymphoma;PET Clinics;2024-04

5. Значение ПЭТ, совмещенной с КТ, при диффузной В-крупноклеточной лимфоме: история вопроса, эволюция представлений и современные возможности метода (обзор литературы);Clinical Oncohematology;2024-02-20